Rabia Ozden
Chief Tech/Sci/R&D Officer bei OCULAR THERAPEUTIX, INC.
Vermögen: 1 Mio $ am 31.03.2024
Profil
Rabia Gurses Ozden is an Independent Director at Adverum Biotechnologies, Inc. and the Chief Medical Officer at Ocular Therapeutix, Inc. She previously served as the Executive Medical Director-Ophthalmology at Quark Pharmaceuticals, Inc. from 2011 to 2014.
She also held the position of Vice President & Head-Clinical Ophthalmology at GSK Plc.
From 2015 to 2018, she worked as the Vice President-Clinical Research & Development at Beacon Therapeutics (USA), Inc. Additionally, she was an Assistant Professor at New York Medical College.
In 2019, she briefly served as the Chief Medical Officer at Nightstar Therapeutics Ltd.
and later became the Chief Development Officer at Akouos, Inc. from 2019 to 2021.
Dr. Ozden obtained her doctorate degree from Hacettepe University.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
OCULAR THERAPEUTIX INC
0,10% | 05.02.2024 | 153 054 ( 0,10% ) | 1 Mio $ | 31.03.2024 |
09.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Rabia Ozden
Unternehmen | Position | Beginn |
---|---|---|
OCULAR THERAPEUTIX, INC. | Chief Tech/Sci/R&D Officer | 08.01.2021 |
ADVERUM BIOTECHNOLOGIES, INC. | Director/Board Member | 17.03.2022 |
Ehemalige bekannte Positionen von Rabia Ozden
Unternehmen | Position | Ende |
---|---|---|
AKOUOS | Corporate Officer/Principal | 01.01.2021 |
NIGHTSTAR THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 01.12.2019 |
APPLIED GENETIC TECHNOLOGIES CORPORATION | Chief Tech/Sci/R&D Officer | 01.03.2018 |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | 01.01.2014 |
New York Medical College | Corporate Officer/Principal | - |
Ausbildung von Rabia Ozden
Hacettepe University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
OCULAR THERAPEUTIX, INC. | Health Technology |
GSK PLC | Health Technology |
ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
Beacon Therapeutics (USA), Inc.
Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
Nightstar Therapeutics Ltd.
Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
Akouos, Inc.
Akouos, Inc. BiotechnologyHealth Technology Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA. | Health Technology |